The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity

Immune checkpoint inhibitors against PD-1/PD-L1 yield improved survival rates of KRAS-mutant NSCLC patients, who conferred a poor prognosis without effective targeted therapy until now. Yet, the underlying association between KRAS mutations and immune responses remains unclear. We performed an integ...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer letters 2020-02, Vol.470, p.95-105
Hauptverfasser:	Liu, Chengming, Zheng, Sufei, Jin, Runsen, Wang, Xinfeng, Wang, Feng, Zang, Ruochuan, Xu, Haiyan, Lu, Zhiliang, Huang, Jianbing, Lei, Yuanyuan, Mao, Shuangshuang, Wang, Yalong, Feng, Xiaoli, Sun, Nan, Wang, Yan, He, Jie
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma Cancer therapies CD8 antigen Chemotherapy Cloning Gene expression Immune checkpoint inhibitors Immune response Immune system Immunogenicity Immunotherapy Inflammation Inhibitors K-Ras protein Kinases KRAS Lung cancer Lymphocytes Metastasis Monoclonal antibodies Mutation Non-small cell lung carcinoma NSCLC Patients PD-1 protein PD-L1 PD-L1 protein Phenotypes Schedules Small cell lung carcinoma TILs TMB Tumor-infiltrating lymphocytes Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!